Transpara 1.7.0

K210404

ScreenPoint Medical B.V. · cleared 2021-06-02 · product code QDQ · Radiology

Premarket evidence — what FDA accepted

Device typesamd
source quote (p.6)
Transpara® is a software only application designed to be used by physicians to improve interpretation of digital mammography and digital breast tomosynthesis.
AlgorithmDeep learning algorithms
source quote (p.6)
'Deep learning' algorithms are applied to FFDM images and DBT slices for recognition of suspicious calcifications and soft tissue lesions (including densities, masses, architectural distortions, and asymmetries). Algorithms are trained with a large database of biopsy-proven examples of breast cancer, benign abnormalities, and examples of normal tissue.
Adaptive (vs locked)No
PCCPFDA source did not state this
Cybersecurity addressedFDA source did not state this

Validation studies (1)

Retrospective clinical

n=9,122 cases

endpoints: Sensitivity; False Positive Rate; AUC

standards: IEC 62366-1 Edition 1.1 2020-06, IEC 62366-1 Edition 1.0 2015-02 [Including CORRIGENDUM 1 (2016)], ISO 14155 Third edition 2020-07, ISO 14155 Second edition 2011-02-01, ISO 14971:2019, IEC 62304:2015, ISO 15223-1 Third Edition 2016-11-01

Reported performance (2 observations)

sensitivity0.947CI 91.7-96.7
source quote (p.10)
For 2D, the sensitivity for calcifications is 94.7% (95% CI: 91.7-96.7) at a false positive rate of 0.11 FP/image.
aurocas written: “auc0.949
source quote (p.10)
For 2D, AUC of the device is 0.949, which is higher is non-inferior in comparison to the AUC of 0.929 of the predicate device.

Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.

Predicate network

Postmarket — what happened after clearance

0
recalls in product code, 24mo
0
MAUDE reports in code, 12mo
vs code's own 3-yr baseline
3
drift signals on this device
  • re_clearance

    The FDA AI/ML device list shows a newer 510(k) K241831 (decision 2024-11-25) from ScreenPoint Medical B.V. for a matching device line ("Transpara (2.1.0)") — a new clearance for the same line is a change event.

    first seen 2026-07-08 · k_number:K241831

  • re_clearance

    The FDA AI/ML device list shows a newer 510(k) K232096 (decision 2023-12-11) from Screenpoint Medical B.V. for a matching device line ("Transpara Density 1.0.0") — a new clearance for the same line is a change event.

    first seen 2026-07-08 · k_number:K232096

  • re_clearance

    The FDA AI/ML device list shows a newer 510(k) K221347 (decision 2022-08-03) from ScreenPoint Medical B.V. for a matching device line ("Transpara 1.7.2") — a new clearance for the same line is a change event.

    first seen 2026-07-08 · k_number:K221347

Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.

Reimbursement — how devices like this got paid

Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).

RIGOR™ Precedent · public FDA/CMS data · descriptive decision-support, not regulatory or reimbursement advice. Share this page: radar.healthai.com/precedent/device/K210404